Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib.

The proteasome inhibitor bortezomib (Velcade) is prescribed for the treatment of multiple myeloma. Clinically achievable concentrations of bortezomib cause less than 85% inhibition of the chymotrypsin-like activity of the proteasome, but little attention has been paid as to whether in vitro studies...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Tamer B Shabaneh, Sondra L Downey, Ayrton L Goddard, Michael Screen, Marcella M Lucas, Alan Eastman, Alexei F Kisselev
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Online Access:	http://europepmc.org/articles/PMC3584083?pdf=render